Colorectal Cancer Treatment and Survival: the Experience of Major Public Hospitals in South Australia over three Decades

Roder, David; Karapetis, Christos S.; Wattchow, David; Moore, James; Singhal, Nimit; Joshi, Rohit; Keefe, Dorothy; Fusco, Kellie; Powell, Kate; Eckert, Marion; Price, Timothy

doi:10.7314/apjcp.2015.16.6.2431

Cited by 35 publications

(70 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing use of neoadjuvant therapies, endocrine therapies, and the introduction of second-and third-generation chemotherapy agents have resulted in improvements in survival for women diagnosed with breast cancer [18]. The increase in treatment of surgical [19] and to the reported differences in colorectal cancer survival between the USA and Europe [20]. Similarly, for stomach cancer, reductions in perioperative morbidity and the use of extended lymphadenectomy in early-stage tumors, along with continued improvements in chemotherapeutic regimens for stage III tumors, have been thought to have contributed to improvements in survival [21].…”

Section: Discussionmentioning

confidence: 99%

Temporal changes in loss of life expectancy due to cancer in Australia: a flexible parametric approach

Baade

Youlden

Andersson

et al. 2016

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Temporal changes in loss of life expectancy due to cancer in Australia: a flexible parametric approach

Baade

Youlden

Andersson

et al. 2016

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…Postcode of residence was registered to indicate: (1) socio-economic quartile, using the Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socioeconomic Disadvantage; and (2) geographic remoteness (classified as metropolitan, regional and remote) [16, 17]. These variables were chosen to investigate and adjust for potential confounding from socio-demographic associations with treatment and survival.…”

Section: Methodsmentioning

confidence: 99%

“…Underlying causes-of-death were corrected when clinical data available to the registry indicated this to be appropriate [13]. The extent of loss to follow-up of deaths has been checked on many occasions through active tracing and comparison with external case series, and found to be minimal, with little effect on calculated survivals [13, 17, 19]. …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Using hospital registries in Australia to extend data availability on vulval cancer treatment and survival

Roder

Davy²,

Selva-Nayagam

et al. 2018

BMC Cancer

Self Cite

View full text Add to dashboard Cite

BackgroundThe value of hospital registries for describing treatment and survival outcomes for vulval cancer was investigated. Hospital registry data from four major public hospitals in 1984–2016 were used because population-based data lacked required treatment and outcomes data. Unlike population registries, the hospital registries had recorded FIGO stage, grade and treatment.MethodsUnadjusted and adjusted disease-specific survival and multiple logistic regression were used. Disease-specific survivals were explored using Kaplan-Meier product-limit estimates. Hazards ratios (HRs) were obtained from proportional hazards regression for 1984–1999 and 2000–2016. Repeat analyses were undertaken using competing risk regression.ResultsFive-year disease-specific survival was 70%, broadly equivalent to the five-year relative survivals reported for Australia overall (70%), the United Kingdom (70%), USA (72%), Holland (70%), and Germany (Munich) (68%). Unadjusted five-year survival tended to be lower for cancers diagnosed in 2000–2016 than 1984–1999, consistent with survival trends reported for the USA and Canada, but higher for 2000–2016 than 1984–1999 after adjusting for stage and other covariates, although differences were small and did not approach statistical significance (p ≥ 0.40). Surgery was provided as part of the primary course of treatment for 94% of patients and radiotherapy for 26%, whereas chemotherapy was provided for only 6%. Less extensive surgical procedures applied in 2000–2016 than 1984–1999 and the use of chemotherapy increased over these periods. Surgery was more common for early FIGO stages, and radiotherapy for later stages with a peak for stage III. Differences in treatment by surgery and radiotherapy were not found by geographic measures of remoteness and socioeconomic status in adjusted analyses, suggesting equity in service delivery.ConclusionsThe data illustrate the complementary value of hospital-registry data to population-registry data for informing local providers and health administrations of trends in management and outcomes, in this instance for a comparatively rare cancer that is under-represented in trials and under-reported in national statistics. Hospital registries can fill an evidence gap when clinical data are lacking in population-based registries.

show abstract

“…Up to 20% of patients diagnosed with early-stage CRC (stage I or II) and up to 30% with regional spread to lymph nodes or adjacent organs (stage III) have relapsed by 5 years after "curative" surgery (2,11). Furthermore, the introduction of laparoscopic surgery for CRC has not altered the 5-year survival rates after curative surgery compared with open surgery (12 (6).…”

Section: Introductionmentioning

confidence: 99%

Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer—20 Years of Progress

Hardingham

Grover

Winter

et al. 2015

Mol Med

123

104

View full text Add to dashboard Cite

Circulating tumor cells (CTC) may be defined as tumor-or metastasis-derived cells that are present in the bloodstream. The CTC pool in colorectal cancer (CRC) patients may include not only epithelial tumor cells, but also tumor cells undergoing epithelial-mesenchymal transition (EMT) and tumor stem cells. A significant number of patients diagnosed with early stage CRC subsequently relapse with recurrent or metastatic disease despite undergoing "curative" resection of their primary tumor. This suggests that an occult metastatic disease process was already underway, with viable tumor cells being shed from the primary tumor site, at least some of which have proliferative and metastatic potential and the ability to survive in the bloodstream. Such tumor cells are considered to be responsible for disease relapse in these patients. Their detection in peripheral blood at the time of diagnosis or after resection of the primary tumor may identify those early-stage patients who are at risk of developing recurrent or metastatic disease and who would benefit from adjuvant therapy. CTC may also be a useful adjunct to radiological assessment of tumor response to therapy. Over the last 20 years many approaches have been developed for the isolation and characterization of CTC. However, none of these methods can be considered the gold standard for detection of the entire pool of CTC. Recently our group has developed novel unbiased inertial microfluidics to enrich for CTC, followed by identification of CTC by imaging flow cytometry. Here, we provide a review of progress on CTC detection and clinical significance over the last 20 years.

show abstract

Colorectal Cancer Treatment and Survival: the Experience of Major Public Hospitals in South Australia over three Decades

Cited by 35 publications

References 24 publications

Temporal changes in loss of life expectancy due to cancer in Australia: a flexible parametric approach

Temporal changes in loss of life expectancy due to cancer in Australia: a flexible parametric approach

Using hospital registries in Australia to extend data availability on vulval cancer treatment and survival

Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer—20 Years of Progress

Contact Info

Product

Resources

About